Press Releases

05.31.2025

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

05.30.2025

Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

05.22.2025

Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer

05.19.2025

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

04.29.2025

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

04.26.2025

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

04.24.2025

Pfizer Announces 2025 Shareholder Meeting Preliminary Results

04.23.2025

Pfizer Declares Second-Quarter 2025 Dividend

04.23.2025

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting

04.16.2025

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

04.14.2025

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

04.10.2025

Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24